Further future studies are warranted to firstly validate other modulatory effects of regorafenib on different P2X7 receptor signaling pathways involved in breast cancer pathogenesis using different breast cancer cell line, and secondary to investigate this promising therapeutic insight in different human cancers, such as colon cancer. This evidence concerns the gene P2RX7 and colonic neoplasm.